News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,089 Results
Type
Article (39982)
Company Profile (333)
Press Release (654774)
Section
Business (206767)
Career Advice (2055)
Deals (35813)
Drug Delivery (88)
Drug Development (82131)
Employer Resources (172)
FDA (16158)
Job Trends (15119)
News (349444)
Policy (32762)
Tag
Academia (2550)
Alliances (49884)
Alzheimer's disease (1253)
Approvals (16090)
Artificial intelligence (133)
Bankruptcy (355)
Best Places to Work (11655)
Biotechnology (239)
Breast cancer (121)
Cancer (1096)
Cardiovascular disease (98)
Career advice (1711)
Cell therapy (239)
Clinical research (65290)
Collaboration (394)
Compensation (203)
COVID-19 (2553)
C-suite (97)
Data (1137)
Diabetes (152)
Diagnostics (6159)
Earnings (85843)
Employer resources (150)
Events (111877)
Executive appointments (316)
FDA (16702)
Funding (355)
Gene therapy (181)
GLP-1 (601)
Government (4365)
Healthcare (18749)
Infectious disease (2638)
Inflammatory bowel disease (108)
Interviews (325)
IPO (16535)
Job creations (3831)
Job search strategy (1464)
Layoffs (426)
Legal (7902)
Lung cancer (170)
Manufacturing (180)
Medical device (13190)
Medtech (13195)
Mergers & acquisitions (19357)
Metabolic disorders (409)
Neuroscience (1533)
NextGen Class of 2024 (6558)
Non-profit (4483)
Northern California (1487)
Obesity (234)
Opinion (196)
Patents (102)
People (57122)
Phase I (20317)
Phase II (28819)
Phase III (21368)
Pipeline (459)
Postmarket research (2564)
Preclinical (8642)
Radiopharmaceuticals (246)
Rare diseases (220)
Real estate (6013)
Regulatory (21777)
Research institute (2332)
Resumes & cover letters (354)
Southern California (1311)
Startups (3644)
United States (13687)
Vaccines (561)
Weight loss (174)
Date
Today (1)
Last 7 days (674)
Last 30 days (3590)
Last 365 days (36205)
2024 (33244)
2023 (40659)
2022 (51785)
2021 (56341)
2020 (54540)
2019 (46983)
2018 (35386)
2017 (32635)
2016 (32060)
2015 (38110)
2014 (32005)
2013 (26893)
2012 (29013)
2011 (29668)
2010 (27706)
Location
Africa (736)
Arizona (194)
Asia (38406)
Australia (6199)
California (3358)
Canada (1299)
China (258)
Colorado (149)
Connecticut (157)
Europe (82734)
Florida (465)
Georgia (116)
Illinois (344)
Indiana (198)
Kansas (96)
Maryland (586)
Massachusetts (2657)
Michigan (158)
Minnesota (275)
New Jersey (965)
New York (970)
North Carolina (749)
Northern California (1487)
Ohio (140)
Pennsylvania (851)
South America (1116)
Southern California (1311)
Texas (473)
Utah (91)
Washington State (368)
695,089 Results for "kiromic biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial.
June 20, 2024
·
7 min read
Drug Development
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial.
June 6, 2024
·
6 min read
Drug Development
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
Kiromic BioPharma, Inc. announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel ™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
May 20, 2024
·
6 min read
Drug Development
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
May 29, 2024
·
6 min read
Drug Development
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
April 2, 2024
·
6 min read
Drug Development
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic BioPharma, Inc. announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™.
April 24, 2024
·
8 min read
Press Releases
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
October 8, 2024
·
6 min read
Drug Development
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial.
March 19, 2024
·
6 min read
Drug Development
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).
March 1, 2024
·
5 min read
Press Releases
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation
September 19, 2024
·
4 min read
1 of 69,509
Next